2D cell model. It is easy to lose the genetic heterogeneity of the original tumor after passage, dominant clonal selection occurs, and the clinical correlation is low. Compared with the 2D cell model, 3D cells or organoids can provide more biologically relevant results, simplifying and accelerating the drug evaluation process. Since the small intestinal organoids were first established in 2009, organoid research has extended to multiple tissue systems and has become one of the most popular technologies in the field of life sciences at present. We are very honored that Agilent BioTek's technology and platform are able to participate in it, joining researchers in creating a great cause in life sciences and contributing to the sustainable development of human health.
On Wednesday 19th (Wednesday) at 14:00, Agilent Cell Analysis Scholars Forum will focus on the topic of organoid culture and transformation application, and two young scholars will share with us their discoveries in organoid research and application transformation. We look forward to all colleagues taking the time to attend the meeting and participate in the exchange!
Chen Wei Doctor
Seventh Affiliated Hospital of Sun Yat-sen University
First Affiliated Hospital of Sun Yat-sen University Doctor of Surgery, postdoctoral fellow at the Seventh Affiliated Hospital of Sun Yat-sen University, assistant researcher. For more than ten years, we have established a large sample gastrointestinal tumor PDX model library and an organoid model library, and used organoids to carry out basic tumor research and individual tumor treatment. In-depth research has been conducted in the fields of organoid modeling, high-throughput organoid drug screening, and clinical application of organoid drug sensitivity.
Liu Dongdong Dr.
Academic Engineering Institute of Chinese Academy of Sciences
Chemical Biology D. He graduated from Northwest A&F University in 2020 and is currently a postdoctoral fellow in the Institute of Process Engineering of Chinese Academy of Sciences. He is mainly engaged in the design of organ chips and the development of subsequent medical screening platforms. He has developed a variety of organ chip platforms, such as intestinal absorption organ chips, liver metabolism and toxic organ chips, kidney organ chips, tumor cell immune chips, skin chips, organoid chips and other chips. At the same time, based on organ chip technology, it mainly conducts systematic research on the absorption, metabolism and toxicity of functional sugar drugs.
Zhao Liming BioTek Marketing Manager
Agilent Technology (China) Co., Ltd.
Molecular Biology Master, Senior Marketing Manager of Laboratory Solutions in Agilent Greater China, has worked in the marketing department of Gene Co., Ltd., and has nearly ten years of experience in technology promotion and support services in the fields of molecular biology, cell biology , immunology and other fields. Have a deep understanding of Agilent BioTek technology and applications.
